Wuhan University Zhongnan Hospital Licenses Novel FRC-Derived Exosome Therapy for Sepsis-Induced Acute Kidney Injury to Hangzhou Exosome Biomaterials for RMB 200,000

Recently, Zhongnan Hospital of Wuhan University plans to commercialize a key invention patent. The patent is titled“Application of Exosomes Derived from Fibroblastic Reticular Cells in the Preparation of Drugs for Treating and/or Preventing Sepsis-Associated Acute Kidney Injury”, priced by the hospital through negotiated pricing,RMB 200,000RMB transferred to Hangzhou Exosome Biomaterials Technology Co., Ltd. This achievement wasLi Yiming, Peng Zhiyong, Zhang Jing, Suo Jinmeng, Liu Ye, Hu Chang, Wang Fengyun, et al.Completed jointly by researchers.

The core content of this patent isFirst proposed and validated the use of exosomes secreted by fibroblastic reticular cells (FRCs)，for the preparation of drugs for treating sepsis-induced acute kidney injury. Its innovation lies in the fact that it not onlyPioneered a specific method for the efficient isolation and culture of fibroblastic reticular cells (FRCs) from adipose tissue, as well as the extraction of their exosomes., more importantly, it reveals a previously unreported novel medical application of this exosome—it canRegulation of the NLRP3/Caspase-1 Signaling Pathway, effectively mitigating pyroptosis of renal cells, thereby significantly improving renal function and increasing survival rates in animal models.Compared with traditional cell therapies, exosomes offer significant advantages in terms of high stability and ease of storage and use, providing a novel therapeutic strategy with strong translational potential for this critical clinical condition.

The advent of this patent addresses a severe clinical reality: globally, sepsis is one of the leading causes of death among patients in intensive care units (ICUs), with acute kidney injury (AKI) being its most common and lethal complication. Statistics indicate that approximately 50% of patients with sepsis develop AKI, further exacerbating their already critical condition. Current clinical management primarily relies on symptomatic treatments, such as anti-infective therapy and organ function support (e.g., renal replacement therapy). While these interventions can temporarily maintain vital signs, they fail to fundamentally repair damaged renal tissue or halt the progressive nature of the injury.

A deeper predicament lies in the “passivity” of current therapeutic approaches—existing treatments are akin to firefighters battling an already raging fire, yet they lack the capacity to prevent the spread of damage or repair injured structures. Due to an insufficient understanding of the precise molecular mechanisms by which sepsis induces kidney injury, clinical practice has long lacked a “root-cause” strategy capable of proactively intervening in the injury process and promoting renal repair. This therapeutic gap not only contributes to persistently high patient mortality rates but also results in substantial consumption of medical resources and a significant societal burden.

This patented technology was developed specifically to overcome this clinical dilemma. Moving beyond mere “symptom control,” it directly addresses the core issue: how to proactively protect nephrons from destruction by inflammatory storms and reactivate their self-repair capabilities. This innovation starts at the microscopic level of cell communication, exploring a novel therapeutic pathway distinct from traditional pharmacological interventions.

The innovation of this patent is not an improvement at a single node, but rather one that spans across“Source Cells—Manufacturing Process—Mechanism of Action—Final Product”the construction of a complete technical system, forming a solid technological moat.

First, there is source innovation in treatment strategies.This patent is the first to“Exosomes Derived from Fibroblastic Reticular Cells (FRCs)” and “Treatment of Sepsis-Associated Acute Kidney Injury”These two concepts are creatively linked. This is not merely a shift in material application, but rather a precision biotherapeutic strategy proposed based on a profound understanding of the immunomodulatory functions of fibroblastic reticular cells (FRCs) as a specific stromal cell population, thereby opening a novel therapeutic window for clinical practice.

Second, independent innovation in core processes.To implement the aforementioned strategies, the R&D team independently developed a high-purity, high-yield preparation “code.” This includes specific protocols for the primary isolation of FRCs from adipose lymphoid tissue.Mixed Enzyme Formula, which can highly selectively promote the growth of FRCsChemically Defined Serum-Free Culture Medium, as well as the standardized process for the final isolation and identification of exosomes. This manufacturing process ensures the stability and controllability of active ingredients, serving as the cornerstone for the translation of research findings into practical applications.

Third, it is the innovation of mechanisms with scientific depth.The patent goes beyond the level of “efficacy” to deeply reveal the scientific essence of “why it works.” The study is the first to elucidate that FRC exosomes act throughInhibition of the NLRP3/Caspase-1 Signaling Pathwayto mitigate “pyroptosis” of renal cells, thereby exerting a protective effect. This mechanistic insight builds a molecular bridge linking cellular-level phenomena with in vivo therapeutic efficacy, providing a solid theoretical foundation for the technology.

Fourth, iterative innovation in product form.Unlike the traditional approach of directly transplanting live cells, this patent selects exosomes as the final product due to their superior translational advantages. This strategy circumvents the challenges associated with cell therapy, including cell survival, tumorigenicity, immune rejection, and transportation and storage difficulties. By leveraging the high stability, ease of standardized production, and enhanced safety profile of exosomes, it significantly lowers the technical barriers and risks involved in translating laboratory findings into clinical industrialization.

In summary, the excellence of this patent lies in its completion of a “zero-to-one” closed-loop design, transforming a biological discovery into a translatable technological solution. Each step incorporates substantive innovation, collectively constituting its core value. However, this breakthrough did not emerge in a vacuum; rather, it arose against the grand backdrop of intense global competition in cutting-edge therapies and accelerated industry development.

On a global scale, exosome therapy has emerged as a new frontier in the biopharmaceutical industry, with a robust pipeline targeting a wide range of diseases, including acute kidney injury.The global exosome therapy market is experiencing explosive growth and is projected to reach $309.6 billion by 2035. Amid this surge, more than 30 companies are developing innovative therapies for acute kidney injury (AKI), with many focusing on cutting-edge approaches such as regenerative medicine and cell/exosome-based interventions. Currently, leading exosome therapies are primarily concentrated in oncology, neurological disorders (e.g., Aruna Bio’s AB126 program for stroke), and medical aesthetics. In the realm of sepsis treatment, non-exosome innovative devices—such as Selective Cell Adsorption (SCA) devices—have already received FDA approval for use in pediatric patients, underscoring the unmet clinical needs and the diverse technological competition within this field.

Focusing on the domestic market, China's exosome industry, though starting slightly later, has been developing rapidly and is transitioning from technological accumulation to industrial synergy and clinical translation.China’s exosome market reached a scale of approximately RMB 2.3 billion in 2024 and has maintained rapid growth. Domestic companies, such as Beijing Enze Kangtai, have established comprehensive capabilities ranging from engineered exosome platforms to GMP-compliant manufacturing, and are advancing clinical research in areas such as neural repair. Of greater significance is the accelerating integration among industry, academia, and research institutions in China. For instance, the recently established “Extracellular Vesicle Industry-Academia-Research Innovation Alliance” in Suzhou brings together more than 200 leading institutions and over 30 enterprises from both China and abroad, aiming to systematically address core bottlenecks from large-scale production to clinical translation. This marks China’s ongoing effort to build a full-chain innovation ecosystem in this field.

In summary, the commercialization of this patent by Zhongnan Hospital of Wuhan University comes at a critical juncture where the global exosome industry is experiencing explosive growth and China’s domestic ecosystem is taking shape.Amidst the global landscape of rapidly advancing cutting-edge therapies and China’s increasingly robust industrial support system, this technology has secured a differentiated competitive edge through its unique fibrous mesh-like cellular origin and well-defined mechanism of action against sepsis-associated acute kidney injury. This successful translation from bench to bedside is not merely a triumph of a single technology, but also a vivid microcosm of China’s frontier biomedicine integrating into the global innovation network and vying for leadership in future therapeutic frontiers.